LEADER 01438oam  2200457   450 
001 9910717171103321
005 20220218090143.0
035   $a(CKB)5470000002528503
035   $a(OCoLC)1274026019
035   $a(OCoLC)995470000002528503
035   $a(EXLCZ)995470000002528503
100   $a20210621d2021      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdacontent
183   $acr$2rdacarrier
200 10$aBiomedical research $einformation on federal contributions to remdesivir: report to congressional committees /$fCandice N. Wright
210  1$aWashington, DC :$cUnited States Government Accountability Office,$d2021.
215   $a1 online resource (ii, 35 pages) $cillustrations
300   $a"March 2021."
300   $a"GAO-21-272."
320   $aIncludes bibliographical references.
517   $aBiomedical research 
606   $aAntiviral agents$zUnited States
606   $aCOVID-19 (Disease)$xTreatment
606   $aCOVID-19 (Disease)$xTreatment$2fast
615  0$aAntiviral agents
615  0$aCOVID-19 (Disease)$xTreatment.
615  7$aCOVID-19 (Disease)$xTreatment.
702   $aWright$b Candice N.
801  0$bS2H
801  1$bS2H
801  2$bOCLCF
801  2$bGPO
801  2$bOCLCO
801  2$bGPO
906   $aBOOK
912   $a9910717171103321
996   $aBiomedical research$9799310
997   $aUNINA